Compare Amylx Pharmaceuticals Inc (AMLX) vs PubMatic Inc (PUBM) Price & Performance

AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.

Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.

PUBM's stock surged 31.9% to $17.78, reflecting strong investor optimism following a Q2 2026 earnings beat with 10.5% revenue growth and improved profitability in mobile app and CTV segments. Technical indicators show a bullish trend with support at $17 and resistance at $18, though RSI levels suggest overbought conditions. The company maintains a robust balance sheet with $120M in cash and positive operating cash flow of $81.06M in 2025, despite a net loss of -$14.46M. Recent leadership changes, including the appointment of a new Global Chief Revenue Officer, aim to accelerate growth amid AI-driven advertising transformations.

The outlook for PUBM is cautiously optimistic, with a consensus price target of $21.50 offering 21% upside potential. Key opportunities include double-digit revenue growth in high-margin segments and AI product adoption, but risks persist from competitive pressures, profitability challenges, and reliance on digital advertising cyclicality. Investors should weigh the strong analyst buy ratings against elevated valuation multiples and execution risks in a dynamic market.